PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials

BACKGROUND: To date, none of randomised trials aim to compare the efficacy of programmed death 1 (PD-1) inhibitor plus chemotherapy and bevacizumab plus chemotherapy as first-line treatment for non-squamous non-small-cell lung cancer (NSCLC). This analysis pooled prospective data to compare the surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Xiangjiao, Chen, Yu, Xing, Ligang, Liu, Xinchao, Zhao, Kaikai, Jiang, Liyang, Zhang, Li, Zhou, Caicun, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Lung Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472163/
http://dx.doi.org/10.1136/bmjresp-2022-001294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472163/
http://dx.doi.org/10.1136/bmjresp-2022-001294

Ejemplares similares